Michael J. Carr

838 total citations
32 papers, 355 citations indexed

About

Michael J. Carr is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Michael J. Carr has authored 32 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Michael J. Carr's work include Cutaneous Melanoma Detection and Management (16 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (6 papers). Michael J. Carr is often cited by papers focused on Cutaneous Melanoma Detection and Management (16 papers), CAR-T cell therapy research (8 papers) and Immunotherapy and Immune Responses (6 papers). Michael J. Carr collaborates with scholars based in United States, Netherlands and Australia. Michael J. Carr's co-authors include Jonathan S. Zager, James Sun, Nikhil I. Khushalani, Vernon K. Sondak, Jane L. Messina, Franz O. Smith, C. Wayne Cruse, Tapan Padhya, Amod A. Sarnaik and Zeynep Eroglu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Michael J. Carr

31 papers receiving 348 citations

Peers

Michael J. Carr
Marcus L. Frohm United States
Anja Schöpflin Germany
Juan A. Santamaria‐Barria United States
M.-F. Avril France
Alessia Paganotti Italy
Giuseppe Macripò Italy
A. Vilalta Spain
Ying Qian China
Nathan T. Harvey Australia
Hongming Huang China
Marcus L. Frohm United States
Michael J. Carr
Citations per year, relative to Michael J. Carr Michael J. Carr (= 1×) peers Marcus L. Frohm

Countries citing papers authored by Michael J. Carr

Since Specialization
Citations

This map shows the geographic impact of Michael J. Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Carr more than expected).

Fields of papers citing papers by Michael J. Carr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Carr. The network helps show where Michael J. Carr may publish in the future.

Co-authorship network of co-authors of Michael J. Carr

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Carr. A scholar is included among the top collaborators of Michael J. Carr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Carr. Michael J. Carr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Balkin, Daniel M., Gregory J. Tranah, Frederick Wang, et al.. (2023). Lymphoscintigraphy Using Tilmanocept Detects Multiple Sentinel Lymph Nodes in Melanoma Patients. Cancer Control. 30. 2915571823–2915571823. 3 indexed citations
2.
Carr, Michael J., Ayushi S. Patel, Youngchul Kim, et al.. (2023). Atypical Fibroxanthoma: Outcomes from a Large Single Institution Series. Cancer Control. 30. 2915573747–2915573747. 5 indexed citations
3.
Carr, Michael J., et al.. (2023). Managing valvular pathology during LVAD implantation. Indian Journal of Thoracic and Cardiovascular Surgery. 39(S1). 101–113. 1 indexed citations
4.
Shannon, Adrienne B., Richard J. Straker, Michael J. Carr, et al.. (2022). An Internally Validated Prognostic Risk-Score Model for Disease-Specific Survival in Clinical Stage I and II Merkel Cell Carcinoma. Annals of Surgical Oncology. 29(11). 7033–7044. 2 indexed citations
5.
Moncrieff, Marc, Serigne Lo, Richard A. Scolyer, et al.. (2022). Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study. Annals of Surgical Oncology. 29(9). 5937–5945. 10 indexed citations
6.
Shannon, Adrienne B., Richard J. Straker, Michael J. Carr, et al.. (2022). Sentinel lymph node biopsy in patients with T1a cutaneous malignant melanoma: A multicenter cohort study. Journal of the American Academy of Dermatology. 88(1). 52–59. 15 indexed citations
7.
Shannon, Adrienne B., Michael J. Carr, James Sun, et al.. (2022). Patterns of recurrence and prognosis in pathologic stage I and II Merkel cell carcinoma: A multicenter, retrospective cohort analysis. Journal of the American Academy of Dermatology. 88(1). 251–253. 1 indexed citations
8.
Carr, Michael J., et al.. (2022). Genitourinary melanoma: An overview for the clinician. Asian journal of urology. 9(4). 407–422. 5 indexed citations
9.
Carr, Michael J., et al.. (2021). External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. Annals of Surgical Oncology. 29(3). 1637–1644. 2 indexed citations
10.
Broman, Kristy K., Deepti Bettampadi, James Sun, et al.. (2021). Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Annals of Surgical Oncology. 28(12). 6978–6985. 13 indexed citations
11.
Carr, Michael J., Federico A. Monzon, & Jonathan S. Zager. (2021). Sentinel lymph node biopsy in melanoma: beyond histologic factors. Clinical & Experimental Metastasis. 39(1). 29–38. 11 indexed citations
12.
Carr, Michael J., James Sun, Luke D. Rothermel, et al.. (2021). Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. Annals of Surgical Oncology. 29(2). 791–801. 23 indexed citations
13.
Patel, Ayushi S., Michael J. Carr, James Sun, & Jonathan S. Zager. (2021). In-transit metastatic cutaneous melanoma: current management and future directions. Clinical & Experimental Metastasis. 39(1). 201–211. 8 indexed citations
14.
Carr, Michael J., Hidde M. Kroon, & Jonathan S. Zager. (2020). ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. Annals of Surgical Oncology. 27(13). 5119–5120. 1 indexed citations
15.
Sun, James, Danielle Henry, Michael J. Carr, et al.. (2020). Feasibility of Axillary Lymph Node Localization and Excision Using Radar Reflector Localization. Clinical Breast Cancer. 21(3). e189–e193. 26 indexed citations
16.
Carr, Michael J., James Sun, & Jonathan S. Zager. (2020). Isolated limb infusion: Institutional protocol and implementation. Journal of Surgical Oncology. 122(1). 99–105. 7 indexed citations
17.
Sun, James, Michael J. Carr, Zeynep Eroglu, et al.. (2019). Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World Journal of Surgery. 44(4). 1283–1293. 9 indexed citations
18.
Sun, James, Michael J. Carr, & Nikhil I. Khushalani. (2019). Principles of Targeted Therapy for Melanoma. Surgical Clinics of North America. 100(1). 175–188. 43 indexed citations
19.
Ström, T., Michael J. Carr, Jonathan S. Zager, et al.. (2016). Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. Annals of Surgical Oncology. 23(11). 3572–3578. 63 indexed citations
20.
Fontaine, Éric, J. McShane, Michael J. Carr, et al.. (2011). Should we operate on microscopic N2 non-small cell lung cancer?. Interactive Cardiovascular and Thoracic Surgery. 12(6). 956–961. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marcus L. Frohm Breakdown of academic impact, for papers by Anja Schöpflin Breakdown of academic impact, for papers by Juan A. Santamaria‐Barria Breakdown of academic impact, for papers by M.-F. Avril Breakdown of academic impact, for papers by Alessia Paganotti Breakdown of academic impact, for papers by Giuseppe Macripò Breakdown of academic impact, for papers by A. Vilalta Breakdown of academic impact, for papers by Ying Qian Breakdown of academic impact, for papers by Nathan T. Harvey Breakdown of academic impact, for papers by Hongming Huang
Rankless by CCL
2026